MR [Mindray Medical International] 6-K: (Original Filing)

[Mindray Announces Second Quarter 2010 Financial Results Shenzhen, China — August 9, 2010 — Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide announced today its selected unaudited financial results for the second quarter and first half ended June 30, 2010. Highlights for Second Quarter and First Half 2010 — Net revenues were]

MR [Mindray Medical International] 6-K: Mindray Announces Second Quarter 2010 Financial Results Shenzhen,

[Mindray Announces Second Quarter 2010 Financial Results Shenzhen, China — August 9, 2010 — Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide announced today its selected unaudited financial results for the second quarter and first half ended June 30, 2010. Highlights for Second Quarter and First Half 2010 — Net revenues were]

MR [Mindray Medical International] 6-K: (Original Filing)

[Mindray Announces Second Quarter 2010 Financial Results Shenzhen, China August9, 2010 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide announced today its selected unaudited financial results for the second quarter and first half ended June30, 2010. Highlights for Second Quarter and First Half 2010]

MR [Mindray Medical International] 6-K: Mindray Announces Second Quarter 2010 Financial Results Shenzhen,

[Mindray Announces Second Quarter 2010 Financial Results Shenzhen, China August9, 2010 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide announced today its selected unaudited financial results for the second quarter and first half ended June30, 2010. Highlights for Second Quarter and First Half 2010]

CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2010 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [EX-3.1 2 cphi10qex31063010.htm AMENDED AND RESTATED CHARTER] [EMPLOYMENT AGREEMENT April 28 Agreement Company nd Employee XXX XX XXXX Parties This EMPLOYMENT AGREEMENT is made and entered into as of WITNESSETH: WHEREAS, the Company is engaged in the business of develop, manufacture, and market specialty pharmaceutical products in China (the “business”); and WHEREAS, Employee has represented that he has the experience, background and expertise necessary to enable his] [CHINA PHARMA HOLDINGS, INC. 2010 SHARES OPTION AGREEMENT China Pharma Holdings, Inc., Frank Waung This 2010 Shares Option Agreement (the “Agreement”) is made as of April 28, 2010 between 1. Notice of Shares Option Grant You (the “Optionee”) have been granted an option to subscribe for, acquire and purchase common shares in the Company (the “Common Shares”), subject to the] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 9, 2010 -------------------------------- President and Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 9, 2010 --------------------- (principal financial officer and principal accounting officer)]

By | 2016-03-03T20:17:15+00:00 August 9th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x June 30, 2010

[FORM 10-Q (Mark One) x June 30, 2010 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [EX-3.1 2 cphi10qex31063010.htm AMENDED AND RESTATED CHARTER] [EMPLOYMENT AGREEMENT April 28 Agreement Company nd Employee XXX XX XXXX Parties This EMPLOYMENT AGREEMENT is made and entered into as of WITNESSETH: WHEREAS, the Company is engaged in the business of develop, manufacture, and market specialty pharmaceutical products in China (the “business”); and WHEREAS, Employee has represented that he has the experience, background and expertise necessary to enable his] [CHINA PHARMA HOLDINGS, INC. 2010 SHARES OPTION AGREEMENT China Pharma Holdings, Inc., Frank Waung This 2010 Shares Option Agreement (the “Agreement”) is made as of April 28, 2010 between 1. Notice of Shares Option Grant You (the “Optionee”) have been granted an option to subscribe for, acquire and purchase common shares in the Company (the “Common Shares”), subject to the] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 9, 2010 -------------------------------- President and Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 9, 2010 --------------------- (principal financial officer and principal accounting officer)]

By | 2016-03-03T20:19:11+00:00 August 9th, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2010 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [AMENDED AND RESTATED CHARTER cphi10qex31063010.htm 2 EX-3.1] [EMPLOYMENTREEMENT WITNESSETH: WHEREAS, thempany is engaged in the business of develop, manufacture, and marketecialty pharmaceutical products in China (the business); and WHEREAS, Employee has represented that he has the experience, background and expertise necessary to enable his to be thempanys Chief Financial Officer; and WHEREAS, based on such representation, and thempanys reasonable due diligence, thempany] [CHINA PHARMAS, 2010 SHARES OPTIONREEMENT China Pharmas, Frank Waung This 2010 Shares Optionreement (thereement) is made of April 28, 2010 between 1. Notice of Shares Option Grant You (the Optionee) have been granted an option to subscribe for, acquire and purchasemmon shares in thempany (themmon Shares), subject to the terms andnditions of the Plan of] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 9, 2010 -------------------------------- President and Chief Executive Officer cphi10qex321063010.htm 11 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 9, 2010 --------------------- (principal financial officer and principal accounting officer) cpho10qex322063010.htm 12 EX-32.2]

By | 2016-02-07T23:25:14+00:00 August 9th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

GSI [GENERAL STEEL] 10-Q: (Original Filing)

[FORM 10-Q x For the quarterly period ended June 30, 2010 or ¨ General Steel Holdings, Inc. Nevada 41-2079252 (State or other Jurisdiction of (I.R.S. Employer Identification No.) Incorporation or Organization) Room 2315, Kuntai International Mansion Building, Yi No. 12, Chaoyangmenwai Ave. Chaoyang District, Beijing, China 100020 +86(10)58797346 x ¨ ¨ ¨ ¨ Large accelerated filer x Accelerated filer ¨] [18 U.S.C. SECTION 1350, SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Zuosheng Yu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of General Steel Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the] [18 U.S.C. SECTION 1350, SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Chen, certify that: 1. I have reviewed this quarterly report on Form 10-Q of General Steel Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 1) 2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 9, 2010 Zuosheng Yu Chief Executive Officer EX-32.1 4 v192915_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 1) 2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 9, 2010 John Chen Chief Financial Officer EX-32.2 5 v192915_ex32-2.htm]

LEDS [SemiLEDs] S-1/A: AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT UNDER

[AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SEMILEDS CORPORATION Delaware 3674 20-2735523 3F, No.11 Ke Jung Rd., Chu-Nan Site, National Corporate Research Ltd. COPIES TO: Mark J. Lee Jeffrey D. Saper ORRICK, HERRINGTON & SUTCLIFFE LLP WILSON SONSINI GOODRICH & ROSATI Approximate date of commencement of proposed sale to the public: o o o] [Consent of Independent Registered Public Accounting Firm The Board of Directors and Stockholders of SemiLEDs Corporation: We consent to the use of our report, dated August 6, 2010, included herein and to the reference to our firm under the heading “Experts” in the prospectus. Our report, dated August 6, 2010, contains an explanatory paragraph that states that the Company has]

By | 2016-04-03T08:28:26+00:00 August 9th, 2010|Categories: Chinese Stocks, LEDS, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar